Wyeth Says Portfolio Growth Potential Separates It From Other Big Pharmas
Executive Summary
Wyeth expects new products to provide incremental growth, rather than replace lost revenue, given the remaining growth potential for its marketed products, President Bernard Poussot said Oct. 5
You may also be interested in...
Wyeth’s Successful R&D Renovation: Neuroscience Shows Early Returns
Six months after unveiling its "Project Springboard" efficiency initiative, Wyeth is holding up its neurosciences portfolio as an example of the success of the work-in-progress transformation of the company's R&D business
Wyeth’s Successful R&D Renovation: Neuroscience Shows Early Returns
Six months after unveiling its "Project Springboard" efficiency initiative, Wyeth is holding up its neurosciences portfolio as an example of the success of the work-in-progress transformation of the company's R&D business
Wyeth Packaging Problems Lead To Warning Letter, Triphasil-28 Recall
Wyeth failed to adequately investigate cases of contamination involving a packaging extractable for two oral contraceptive drugs manufactured at the firm's Guayama, Puerto Rico facility, FDA states in a recent warning letter